Verona Pharma plc
VRNA
株式のランク
#2227
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
株価
$106.91
最終同期: 2025-10-07
時価総額
$9.09B
変化（1日）
0.00%
変化（1年）
0.00%
国
GB
取引 Verona Pharma plc (VRNA)
カテゴリー
Healthcare
Verona Pharma plc（VRNA）のEPS
June 2025 時点のEPS TTM: $-0.77
Verona Pharma plcの最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-0.77です。2023年末には、EPSは$-0.54で、2022年のEPS$-0.86と減少でした。
Verona Pharma plcのEPS履歴（2005から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-0.77 | -54.71% |
| 2024 | $-1.70 | 214.81% |
| 2023 | $-0.54 | -37.21% |
| 2022 | $-0.86 | 24.64% |
| 2021 | $-0.69 | -52.41% |
| 2020 | $-1.45 | -53.07% |
| 2019 | $-3.09 | 60.65% |
| 2018 | $-1.92 | -23.89% |
| 2017 | $-2.53 | 70.63% |
| 2016 | $-1.48 | -66.16% |
| 2015 | $-4.38 | 121.20% |
| 2014 | $-1.98 | -59.64% |
| 2013 | $-4.90 | 43.91% |
| 2012 | $-3.41 | -36.19% |
| 2011 | $-5.34 | -10.68% |
| 2010 | $-5.98 | 9.91% |
| 2009 | $-5.44 | 41.09% |
| 2008 | $-3.85 | -38.00% |
| 2007 | $-6.22 | 108.58% |
| 2006 | $-2.98 | -3,065.67% |
| 2005 | $0.10 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -2,349.35% |
US
|
|
| $-7.98 | 936.36% |
US
|
|
| $-5.29 | 587.01% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,702.60% |
NL
|
